Sana Biotechnology. has been granted a patent for engineered T cells featuring reduced expression of specific proteins and enhanced CD47 expression. These cells also express a CD22-specific chimeric antigen receptor, potentially improving their therapeutic applications in immunotherapy. GlobalData’s report on Sana Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sana Biotechnology, Viral vectors was a key innovation area identified from patents. Sana Biotechnology's grant share as of June 2024 was 3%. Grant share is based on the ratio of number of grants to total number of patents.
Engineered t cells with hypoimmunogenic properties and cars
The patent US11987628B2 describes an engineered T cell characterized by specific genetic modifications aimed at enhancing its therapeutic potential. The engineered T cell exhibits reduced expression of B2M, CIITA, and/or T cell receptor (TCR)-alpha compared to control T cells. Additionally, it features increased expression of CD47, achieved through the introduction of a first exogenous polynucleotide, and expresses a CD22-specific chimeric antigen receptor (CAR) via a second exogenous polynucleotide. The CAR is designed with a defined antigen binding domain, which includes specific light and heavy chain variable regions, as well as various structural components such as hinge, transmembrane, costimulatory, and intracellular signaling domains.
Further claims detail the specific sequences for the hinge, transmembrane, costimulatory, and intracellular signaling domains, as well as the potential for the engineered T cell to have reduced or absent surface expression of human leukocyte antigen (HLA) class I and II antigens. The patent also outlines methods for inserting the exogenous polynucleotides into the T cell's genome, including the use of viral transduction techniques, particularly employing lentiviral vectors. The engineered T cells can be formulated into pharmaceutical compositions, which may include a pharmaceutically acceptable carrier, thereby providing a basis for potential therapeutic applications in treating diseases such as cancer.
To know more about GlobalData’s detailed insights on Sana Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
